Core Services
Non-dilutive Funding
LBG consultants have the insight, knowledge, and network to match your program with the appropriate government agency and/or opportunities, and employs a unique business model to help navigate the process.
Learn MoreProduct Development
LBG consultants have years of experience across all functional product development disciplines for vaccines, therapeutics, cell and gene therapies, and medical devices and diagnostics; and can provide on-demand expertise and advice at strategic crossroads or as a full-fledged product development team.
Learn MoreStrategic Consulting
LBG consultants support pipeline and portfolio review and analysis, industry benchmarking, market research, asset opportunity and prioritization analysis, due diligence and financial modeling support among other things.
Learn MoreWe provide the depth of expertise necessary to advance your programs, by offering a range of life science services supporting vaccine, therapeutic, medical device and diagnostic product development.
Our Expertise
With proven expertise across a wide spectrum of life science products and sectors, LBG is equipped to deliver effective development and funding solutions for your specific needs. From vaccines to cell & gene therapies to diagnostics to animal health products, we have the depth of expertise to plug into your teams and provide the right guidance and support to help you reach your organizational objectives.
Product and sector expertise include:
- Cell & Gene Therapy
- Vaccine Development
- Therapeutic Products
- Non-Dilutive Funding
- Program Management
- Business Development
Resources
View More ResourcesRecent News
View More NewsChallenges for Biomanufacturing 2024 and Beyond
Georgia Sloboda, LBG’s Managing Director of Chemistry Manufacturing & Controls, will be presenting at the Bioprocessing Venture, Innovation & Partnering Conference on August 21st in Boston. Her topic, the Challenges …
Read MoreSustainable Manufacturing
“Sustainable manufacturing aims to improve on current manufacturing processes and create a far more ecologically friendly system without sacrificing productivity,” states Latham BioPharm Group, part of Sia Partners Patrick Falvey. …
Read More